64.90
+0.15%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Devyser Diagnostics
Its shares trade on Nasdaq Stockholm under the ticker DVYSR.ST. It has been listed since 10 December 2021. In the fiscal year to 31 December 2025, it reported revenue of SEK 250.5m and a net loss of SEK 8.4m. At that date it held total assets of SEK 469.7m and shareholders' equity of SEK 354.3m.
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Dec 2021
- Employees
- 96
- Website
- devyser.com ↗
Leadership
Pay as last reported
- Ms. Mia ArnhultChairman of the BoardSEK 279,000
- Mr. Jan WahlstroemChief Executive Officer
- Ms. Sabina BerlinChief Financial Officer
- Mr. Goran RydinChief Operating Officer
- Ms. Camilla WibergChief Human Resources Officer
- Mr. Michael UhlinChief Scientific Officer
- Mr. Theis KiplingChief Commercial Officer
- Mr. Fredrik DahlDirector, since 2021SEK 144,000
- Ms. Isabelle DucellierDirector
- Mr. Olof EricssonDirector
- Mr. Thomas EklundIndependent Director
- Ms. Pia GideonIndependent DirectorSEK 134,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Devyser Diagnostics AB employs 96 full-time employees in Hagersten, Sweden.
- Devyser Diagnostics AB has developed and launched nearly 30 products for routine diagnostics.
- Devyser Diagnostics AB provides products in over 45 countries across Europe and Asia.
Weaknesses
- Devyser Diagnostics AB's products are used for DNA testing in hereditary diseases and oncology.
- Devyser Diagnostics AB's products are sold directly to end customers or through distributors.
- Devyser Diagnostics AB's business focuses on genetic testing kits for routine diagnostics.
Opportunities
- Devyser Diagnostics AB's Devyser Thrombophilia assay targets hereditary diseases in Europe.
- Devyser Diagnostics AB's Devyser Resolution XY analyzes chromosomes X and Y in oncology.
- Devyser Diagnostics AB's products are used for post-transplantation monitoring in Asia.
Threats
- Devyser Diagnostics AB's products are limited to genetic testing in hereditary diseases and oncology.
- Devyser Diagnostics AB's products are sold in over 45 countries but face competition in Europe.
- Devyser Diagnostics AB's business model relies on direct sales and distributors in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.